AKAO - Melinta Therapeutics: Undervalued And Underappreciated In 2019
Antibiotic resistance is a growing global public health emergency. Melinta Therapeutics (MLNT) has decided to take up the critical mission of overcoming antibiotic resistance with their broad spectrum antibiotic portfolio. Unfortunately, the market doesn’t see the opportunity in addressing this issue and has pummeled MLNT over the past couple of years. Despite the need for new antibiotics, the clinical market hasn’t appreciated the company’s products, and the company has struggled to hit expectations as a result. However, I expect the clinical market acceptance of Melinda's products, and the street’s acceptance of Melinta’s prospects